Fatty acid metabolism is a significant hallmark of cancer cells, and EGCG serves as an effective fatty acid and energy metabolism modulator to suppress CRC via regulation of vital genes accounted for fatty acid de novo synthesis, AMPK activation, improved FASN expression, and declined ATP production in CRC cells (Wang, Pan, et al. 2021; Wang, Yeh, and Chen 2021). This evidence concerns the gene FASN and colorectal carcinoma.